ReviewCureus2025
Efficacy of Real-Time Continuous Glucose Monitoring in Improving Glycemic Outcomes Among Adults With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes (T2D) requires rigorous glycemic control to prevent complications, but traditional self-monitoring of blood glucose (SMBG) offers limited insights. Real-time continuous glucose monitoring (RT-CGM) provides dynamic data to optimize management, although its efficacy in T2D remains debated. This systematic review synthesizes evidence from randomized controlled trials (RCTs) to evaluate RT-CGM's impact on glycemic outcomes in adults with T2D. Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines, we searched PubMed, Scopus, Web of Science, and ClinicalTrials.gov (2015-2025) for RCTs comparing RT-CGM to SMBG/usual care in non-pregnant adults with T2D. Eleven studies met the inclusion criteria. Data were extracted for HbA1c, time in range (TIR), hypoglycemia, and safety. Risk of bias was assessed using Cochrane RoB 2. RT-CGM significantly improved TIR and reduced HbA1c in insulin-treated patients, although benefits varied by intervention frequency and patient subgroup. Episodic use required multiple sessions for sustained HbA1c reduction. Non-insulin-treated cohorts saw smaller HbA1c changes but improved glycemic variability. Treatment satisfaction was consistently higher with RT-CGM. Safety profiles were favorable, with no severe device-related adverse events. RT-CGM enhances glycemic control in T2D, particularly for insulin-treated patients, with structured use yielding the greatest benefits. Clinicians should prioritize individualized protocols and patient education. Future research should address long-term efficacy and cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.